Passage Bio, Inc. (PASG)
4.65
-0.10
(-2.11%)
USD |
NASDAQ |
Sep 04, 16:00
4.68
+0.03
(+0.65%)
Pre-Market: 20:00
Passage Bio SG&A Expense (TTM) : 20.93M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.93M |
| March 31, 2026 | 18.58M |
| December 31, 2025 | 19.88M |
| September 30, 2025 | 19.66M |
| June 30, 2025 | 22.57M |
| March 31, 2025 | 24.56M |
| December 31, 2024 | 24.99M |
| September 30, 2024 | 26.56M |
| June 30, 2024 | 27.49M |
| March 31, 2024 | 29.05M |
| December 31, 2023 | 41.58M |
| September 30, 2023 | 45.88M |
| June 30, 2023 | 48.36M |
| March 31, 2023 | 53.29M |
| December 31, 2022 | 49.34M |
| September 30, 2022 | 55.95M |
| Date | Value |
|---|---|
| June 30, 2022 | 60.26M |
| March 31, 2022 | 62.69M |
| December 31, 2021 | 60.06M |
| September 30, 2021 | 52.99M |
| June 30, 2021 | 45.80M |
| March 31, 2021 | 37.78M |
| December 31, 2020 | 30.11M |
| September 30, 2020 | 23.61M |
| June 30, 2020 | 15.82M |
| March 31, 2020 | 15.82M |
| December 31, 2019 | 11.02M |
| September 30, 2019 | 7.883M |
| June 30, 2019 | 7.883M |
| March 31, 2019 | 0.481M |
| December 31, 2018 | 0.481M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ARS Pharmaceuticals, Inc. | 284.49M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |
| Savara, Inc. | 56.71M |